These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14684678)

  • 41. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
    Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
    Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
    Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI
    Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
    Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
    Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL; Swan VJ; Jamal SA
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?
    Schepers E; Speer T; Bode-Böger SM; Fliser D; Kielstein JT
    Semin Nephrol; 2014 Mar; 34(2):97-105. PubMed ID: 24780466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease.
    Mallamaci F; Tripepi G; Maas R; Malatino L; Böger R; Zoccali C
    J Am Soc Nephrol; 2004 Feb; 15(2):435-41. PubMed ID: 14747391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AGEs and cardiovascular diseases in patients with end-stage renal diseases.
    Nishizawa Y; Koyama H; Inaba M
    J Ren Nutr; 2012 Jan; 22(1):128-33. PubMed ID: 22200429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
    Zhang WR; Tao LJ; Chen BM
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):133-4. PubMed ID: 12575339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon.
    Qunibi WY; Nolan CA; Ayus JC
    Kidney Int Suppl; 2002 Dec; (82):S73-80. PubMed ID: 12410860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease.
    Hov GG; Sagen E; Hatlen G; Bigonah A; Åsberg A; Aasarød K
    Clin Biochem; 2011 Jun; 44(8-9):642-6. PubMed ID: 21406191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease.
    Osanai T; Fujiwara N; Saitoh M; Sasaki S; Tomita H; Nakamura M; Osawa H; Yamabe H; Okumura K
    Blood Purif; 2002; 20(5):466-8. PubMed ID: 12207094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Atherosclerosis and uremia: signifance of non-traditional risk factors].
    Hörl WH
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):220-34. PubMed ID: 12778774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular risk factors in peritoneal dialysis patients revisited.
    Wang AY
    Perit Dial Int; 2007 Jun; 27 Suppl 2():S223-7. PubMed ID: 17556309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The past, presence and future of ADMA in nephrology.
    Kielstein JT; Fliser D
    Nephrol Ther; 2007 Apr; 3(2):47-54. PubMed ID: 17452300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ADMA: its role in vascular disease.
    Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypervolemia, hypoalbuminemia and mitral calcification as markers of cardiovascular risk in peritoneal dialysis patients.
    Querido S; Quadros Branco P; Silva Sousa H; Adragão T; Araújo Gonçalves P; Gaspar MA; Barata JD
    Rev Port Cardiol; 2017 Sep; 36(9):599-604. PubMed ID: 28843932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
    Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
    Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.
    Zobel EH; von Scholten BJ; Reinhard H; Persson F; Teerlink T; Hansen TW; Parving HH; Jacobsen PK; Rossing P
    Cardiovasc Diabetol; 2017 Jul; 16(1):88. PubMed ID: 28697799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease.
    Mittermayer F; Krzyzanowska K; Exner M; Mlekusch W; Amighi J; Sabeti S; Minar E; Müller M; Wolzt M; Schillinger M
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2536-40. PubMed ID: 16931791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.